Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2015 16:01 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell up to...
January 26, 2015 16:30 ET | Source: Aceragen, Inc.

Idera Announces Leadership Appointments

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing...
January 09, 2015 13:00 ET | Source: Aceragen, Inc.

Idera to Present at the 33rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
December 30, 2014 08:00 ET | Source: Aceragen, Inc.

Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia

- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenström's macroglobulinemia - Four-week safety review by Data Review Committee for second dose cohort completed in...
December 15, 2014 09:00 ET | Source: Aceragen, Inc.

Idera Announces Several Key Additions to Management Team

CAMBRIDGE, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare...
December 08, 2014 17:45 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting

- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials - Preclinical data show promise of early-line combination therapy with IMO-8400 and rituximab CAMBRIDGE,...
December 02, 2014 16:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models

CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer...
December 02, 2014 10:12 ET | Source: Aceragen, Inc.

Idera Announces Appointment of Robert A. Doody Jr. as Vice President of Investor Relations and Corporate Communications

CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare...
December 02, 2014 08:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for cancer and rare...
December 01, 2014 16:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Names Vincent J. Milano Chief Executive Officer

-- Appointment brings commercial, operational and financial expertise -- Will build the business to advance programs in cancer and rare diseases -- Dr. Sudhir Agrawal to continue to lead...